BRD2 Upregulation as a Pan-Cancer Adaptive Resistance Mechanism to BET Inhibition
Suyakarn Archasappawat, Juliette Jacques, Eunjung Lee, Chang‐Il Hwang
This study identifies BRD2 upregulation as a common adaptive resistance mechanism to BET inhibitors across cancers and shows that targeting BRD2 or NFYA can enhance BET inhibitor efficacy.
Cellular & Molecular Biology Letters · May 2, 2026Peer-reviewedCancer Biology